Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II MIKE-1 plus gemcitabine and nab-paclitaxel for unresectable pancreatic cancer
jRCT2041210056Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamibarotene in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity and Response rate. Started Mar 2022; status: active, not recruiting.
02
Drugs
tamibarotene
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2041210056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210056.